PARP inhibitors stumble in breast cancer

Nat Biotechnol. 2011 May;29(5):373-4. doi: 10.1038/nbt0511-373.
No abstract available

Publication types

  • News

MeSH terms

  • Alleles
  • Antineoplastic Agents, Alkylating / pharmacology*
  • Antineoplastic Agents, Alkylating / therapeutic use
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / enzymology
  • Clinical Trials as Topic
  • DNA Damage
  • DNA Repair
  • Dacarbazine / analogs & derivatives*
  • Dacarbazine / pharmacology
  • Dacarbazine / therapeutic use
  • Enzyme Inhibitors / pharmacology*
  • Enzyme Inhibitors / therapeutic use
  • Female
  • Genes, BRCA1
  • Genes, BRCA2
  • Humans
  • Poly(ADP-ribose) Polymerase Inhibitors*
  • Temozolomide

Substances

  • Antineoplastic Agents, Alkylating
  • Enzyme Inhibitors
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Dacarbazine
  • Temozolomide